Table 1. The relationship between pathological characteristics and discordance of biomarkers.
[N (%)].
| Demographic or Clinical Characteristic | No. of Patients (N = 482,%) | Estrogen Receptor | Progesterone Receptor | Ki-67 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordant (n = 432) | Discordanc e (n = 50) | P | Concordant (n = 400) | Discordanc e (n = 82) | P | Declined (n = 243) | Concordan t (n = 75) | Increased (n = 130) | P | ||
| Age, years | |||||||||||
| ≤40 | 81(16.8) | 68(84.0%) | 13(16.0%) | 0.066 | 60(74.1%) | 21(25.9%) | 0.019 | 33(43.4%) | 18(23.7%) | 25(32.9%) | 0.079 |
| >40 | 401(83.2) | 364(90.8%) | 37(9.2%) | 340(84.8%) | 61(15.2%) | 210(56.5%) | 57(15.3%) | 105(28.2%) | |||
| Menopausal | |||||||||||
| Premenopaus | 262(54.4) | 233(88.9%) | 29(11.1%) | 0.585 | 212(80.9%) | 50(19.1%) | 0.187 | 131(54.6%) | 39(16.3%) | 70(29.2%) | 0.956 |
| Postmenopau | 220(45.6) | 199(90.5%) | 21(9.5%) | 188(85.5%) | 32(14.5%) | 112(53.8%) | 36(17.3%) | 60(28.8%) | |||
| T Stage | |||||||||||
| T1/0 | 41(8.5) | 37(90.2%) | 4(9.8%) | 0.817 | 35(85.4%) | 6(14.6%) | 0.977 | 19(52.8%) | 9(25.0%) | 8(22.2%) | 0.450 |
| T2 | 313(64.9) | 283(90.4%) | 30(9.6%) | 259(82.7%) | 54(17.3%) | 164(56.0%) | 43(14.7%) | 86(29.4%) | |||
| T3 | 68(14.1) | 60(88.2%) | 8(11.8%) | 56(82.4%) | 12(17.6%) | 30(47.6%) | 15(23.8%) | 18(28.6%) | |||
| T4 | 60(12.5) | 52(86.7%) | 8(13.3%) | 50(83.3%) | 10(16.7%) | 30(53.6%) | 8(14.3%) | 18(32.1%) | |||
| N Stage | |||||||||||
| N0 | 97(20.1) | 90(92.8%) | 7(7.2%) | 0.336 | 85(87.6%) | 12(12.4%) | 0.435 | 49(54.4%) | 14(15.6%) | 27(30.0%) | 0.037 |
| N1 | 283(58.7) | 253(89.4%) | 30(10.6%) | 232(82.0%) | 51(18.0%) | 143(54.8%) | 35(13.4%) | 83(31.8%) | |||
| N2 | 55(11.4) | 50(90.9%) | 5(9.1%) | 43(78.2%) | 12(21.8%) | 26(50.0%) | 12(23.1%) | 14(26.9%) | |||
| N3 | 47(9.8) | 39(83.0%) | 8(17.0%) | 40(85.1%) | 7(14.9%) | 25(55.6%) | 14(31.1%) | 6(13.3%) | |||
| pT Stage | |||||||||||
| pT1/0 | 153(31.7) | 140(91.5%) | 13(8.5%) | 0.734 | 130((85.0%) | 23(15.0%) | 0.933 | 77(50.3%) | 37(24.2%) | 39(25.5%) | 0.331 |
| pT2 | 238(49.4) | 212(89.1%) | 26(10.9%) | 198(83.2%) | 40(16.8%) | 119(50.0%) | 35(14.7%) | 84(35.3%) | |||
| pT3 | 31(6.4) | 28(90.3%) | 3(9.7%) | 25(80.6%) | 6(19.4%) | 14(45.2%) | 7(22.6%) | 10(32.3%) | |||
| pT4 | 60(12.5) | 52(86.7%) | 8(13.3%) | 50(83.3%) | 10(16.7%) | 31(51.7%) | 9(15.0%) | 20(33.3%) | |||
| pN Stage | |||||||||||
| pN0 | 102(21.2) | 90(88.2%) | 12(11.8%) | 0.401 | 89(87.3%) | 13(12.7%) | 0.504 | 55(53.9%) | 17(16.7%) | 30(29.4%) | 0.067 |
| pN1 | 275(57.1) | 223(81.1%) | 52(18.9%) | 220(80.0%) | 55(20.0%) | 148(53.8%) | 23(8.4%) | 104(37.8%) | |||
| pN2 | 60(12.4) | 55(91.7%) | 5(8.3%) | 53(88.3%) | 7(11.7%) | 34(56.7%) | 16(26.7%) | 10(16.7%) | |||
| pN3 | 45(9.3) | 39(86.7%) | 6(13.3%) | 38(84.4%) | 7(15.6%) | 24(53.3%) | 14(31.1%) | 7(15.6%) | |||
| Histology | |||||||||||
| Ductal | 452(93.8) | 404(89.4%) | 48(10.6%) | 0.757 | 372(82.3%) | 80(17.7%) | 0.119 | 228(54.2%) | 69(16.4%) | 124(29.5%) | 0.612 |
| Mixed | 30(6.2) | 28(93.3%) | 2(6.7%) | 28(93.3%) | 2(6.7%) | 15(55.6%) | 6(22.2%) | 6(22.2%) | |||
| Nuclear Grade | |||||||||||
| Ⅰ | 11(2.3) | 11(100.0%) | 0(0.0%) | 0.114 | 8(72.7%) | 3(27.3%) | 0.537 | 8(88.9%) | 0(0.0%) | 1(11.1%) | < .001 |
| Ⅱ | 137(28.4) | 128(93.4%) | 9(6.6%) | 117(85.4%) | 20(14.6%) | 87(68.0%) | 13(10.2%) | 28(21.9%) | |||
| Ⅲ | 106(22.0) | 92(86.8%) | 14(13.2%) | 89(84.0%) | 17(16.0%) | 44(43.1%) | 33(32.4%) | 25(24.5%) | |||
| Unknow | 228(47.3) | ||||||||||
| Therapeutic Evaluation | |||||||||||
| cCR/cPR | 336(69.7) | 298(88.7%) | 38(11.3%) | 0.216 | 273(81.3%) | 63(18.8%) | 161(52.3%) | 51(16.6%) | 96(31.2%) | ||
| cSD | 137(28.4) | 127(92.7%) | 10(7.3%) | 120(87.6%) | 17(12.4%) | 0.229 | 79(60.3%) | 20(15.3%) | 32(24.4%) | 0.102 | |
| cPD | 9(1.9) | 7(77.8%) | 2(22.2%) | 7(77.8%) | 2(22.2%) | 3(33.3%) | 4(44.4%) | 2(22.2%) | |||
| Stage | |||||||||||
| ⅡA | 101(21.0) | 94(93.1%) | 7(6.9%) | 0.234 | 86(85.1%) | 15(14.9%) | 0.752 | 53(57.6%) | 12(13.0%) | 27(29.3%) | 0.393 |
| ⅡB/ⅢA | 282(58.5) | 254(89.8%) | 29(10.2%) | 232(82.0%) | 51(18.0%) | 139(52.7%) | 43(16.3%) | 82(31.1%) | |||
| ⅢB/ⅢC | 99(20.5) | 84(85.7%) | 14(14.3%) | 82(83.7%) | 16(16.3%) | 51(55.4%) | 20(21.7%) | 21(22.8%) | |||
| Subtype | |||||||||||
| Luminal | 224(46.5) | 208(92.9%) | 16(7.1%) | < .001 | 180(80.4%) | 44(19.6%) | < .001 | 128(62.1%) | 19(9.2%) | 59(28.6%) | < .001 |
| Luminal/HER | 80(16.6) | 57(71.3%) | 23(28.8%) | 56(70.0%) | 24(30.0%) | 33(45.8%) | 12(16.7%) | 27(37.5%) | |||
| HER2-rich | 75(15.6) | 68(90.7%) | 7(9.3%) | 70(93.3%) | 5(6.7%) | 36(50.7%) | 16(22.5%) | 19(26.8%) | |||
| TNBC | 83(17.2) | 79(95.2%) | 4(4.8%) | 77(92.8%) | 6(7.2%) | 33(41.3%) | 26(32.5%) | 21(26.3%) | |||
| Unknow | 20(4.2%) | ||||||||||
| NAC Regimens | |||||||||||
| Anthracycline | 38(7.9) | 35(92.1%) | 3(7.9%) | 0.823 | 33(86.8%) | 5(13.2%) | 0.073 | 23(65.7%) | 4(11.4%) | 8(22.9%) | 0.313 |
| Taxane based | 64(13.3) | 58(90.5%) | 6(9.5%) | 59(92.2%) | 5(7.8%) | 37(62.7%) | 7(11.9%) | 15(25.4%) | |||
| E+T both | 380(78.8) | 339(89.2%) | 41(10.8%) | 308(81.1%) | 72(18.9%) | 183(51.7%) | 64(18.1%) | 107(30.2%) | |||
Abbreviations: NAC, neoadjuvant chemotherapy; TNBC, triple negative breast cancer; HER-2, human epidermal growth factor receptor 2; cPR, clinical partial response; cSD, clinical stable disease; cPD, clinical progressive disease; A, Anthracycline; P, paclitaxel.